X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypoglycemia.
Lead Product(s): MBX 1416
Therapeutic Area: Endocrinology Product Name: MBX 1416
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy for hypoparathyroidism. It was designed with the company’s novel, proprietary Precision Endocrine Peptide™ (PEP™) platform technology.
Lead Product(s): MBX 2109
Therapeutic Area: Endocrinology Product Name: MBX 2109
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
MBX 1416 is an investigational long-acting GLP-1 receptor antagonist in development as a potential treatment for Post-Bariatric Hypoglycemia. It was designed using the company’s novel, proprietary PEP platform to prevent the occurrence of severe hypoglycemia.
Lead Product(s): MBX 1416
Therapeutic Area: Endocrinology Product Name: MBX 1416
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Proceeds of the financing will support clinical advancement of its lead product candidate, MBX 2109, an investigational long-acting parathyroid hormone peptide prodrug, which is in development for the treatment of hypoparathyroidism and currently in a Phase 1 clinical trial.
Lead Product(s): MBX 2109
Therapeutic Area: Endocrinology Product Name: MBX 2109
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Wellington Management
Deal Size: $115.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing November 14, 2022
Details:
MBX 2109 is an investigational long-acting parathyroid hormone peptide prodrug in development as a PTH replacement therapy. MBX 2109 was observed to be safe and well tolerated, as compared to placebo.
Lead Product(s): MBX 2109
Therapeutic Area: Endocrinology Product Name: MBX 2109
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
MBX 2109, an investigational PTH prodrug in development designed with novel, proprietary prodrug to provide sustained PTH activity with dosing regimen to simplify an individual’s disease management, while relieving both symptoms of disorder and long-term complications.
Lead Product(s): MBX 2109
Therapeutic Area: Endocrinology Product Name: MBX 2109
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
Proceeds of the financing will support MBX as it advances its preclinical pipeline of peptide therapeutic candidates directed at clinically validated molecular targets.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $34.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
